Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Immunology
• Medical Research

Background:

• Immunotherapy has revolutionized cancer care but has limited impact on breast cancer.
• Triple-negative breast cancer (TNBC) is aggressive with poor prognosis and few treatment options.
• Immune checkpoint inhibitors (ICIs) like pembrolizumab are approved for TNBC, showing promise.

Purpose of the Study:

• To review the successes and challenges of ICI use in TNBC.
• To explore emerging strategies for overcoming resistance and expanding immunotherapy efficacy.
• To outline future research directions for optimizing TNBC treatment.

Main Methods:

• Review of current literature on immunotherapy in TNBC.
• Analysis of clinical trial data for pembrolizumab and other ICIs.
• Discussion of novel combination therapies and biomarkers.

Main Results:

• Pembrolizumab combined with chemotherapy improves outcomes in early-stage and metastatic TNBC (PD-L1 positive).
• Novel strategies like antibody-drug conjugates and dual ICIs are being investigated.
• Neoadjuvant pembrolizumab plus chemotherapy sets a new standard for early-stage TNBC.

Conclusions:

• ICI therapy, particularly pembrolizumab, offers significant benefits for TNBC.
• Further research is needed to optimize ICI timing, patient selection, and combination therapies.
• Future directions include exploring novel agents and biomarkers to improve TNBC treatment outcomes.